Plain-English translation of NCT05956041 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination of two immunotherapy drugs— and —to treat advanced cutaneous T-cell lymphoma (a type of blood cancer that affects the skin) in patients whose cancer has come back or stopped responding to prior treatments. Both medications work by helping your immune system recognize and attack cancer cells. The study will show whether using these two drugs together is safe and effective.
Cutaneous T-cell lymphoma is difficult to treat, especially when it reaches advanced stages or returns after initial therapy. This medication combination aims to give patients a new option when standard treatments have stopped working.
You likely qualify if…
You likely don't qualify if…
You will receive intravenous infusions of both medications on a 6-week cycle. In the first cycle, you'll receive one drug once and the other drug four times; in later cycles, the schedule adjusts to three infusions per 6-week period. You'll come for treatment infusions and regular check-ups (including skin assessments and blood work) to see how your disease responds. The study lasts up to 2 years, though if your cancer fully disappears after 3 months, you may stop treatment sooner and enter a monitoring phase.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
United States